Company news
Fennec Pharmaceuticals Inc. news in 2024
Fennec Pharmaceuticals Inc.'s news releases, calls and decks from 2024, newest first.
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
December 19, 2024
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management
December 18, 2024
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
December 11, 2024
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
November 6, 2024
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
October 30, 2024
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth
October 27, 2024
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
September 4, 2024
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024
August 5, 2024
Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
August 4, 2024
Fennec Pharmaceuticals Announces Management Change
June 30, 2024
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 13, 2024
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
May 6, 2024
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
March 20, 2024
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
March 18, 2024
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
March 16, 2024
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
February 28, 2024
FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
January 31, 2024
Calls in 2024
- Fennec Pharmaceuticals (NASDAQ:FENC) Q3 2024 Earnings Call
Nov 7, 2024
Transcript - Fennec Pharmaceuticals (NASDAQ:FENC) Q2 2024 Earnings Call
Aug 13, 2024
Transcript - Fennec Pharmaceuticals (NASDAQ:FENC) Q4 2023 Earnings Call
May 21, 2024
Transcript - Fennec Pharmaceuticals (NASDAQ:FENC) Q1 2024 Earnings Call
May 14, 2024
Transcript